Ceftaroline Will Earn Peak Year Sales of up to $200 Million in the Community-Acquired Pneumonia Drug Market

Tuesday, March 2, 2010 General News
Email Print This Page Comment
Font : A-A+

Between 2010 and 2015, Ceftaroline is Poised to be the Only Marketed Anti-MRSA Cephalosporin for the Indication, According to New Findings from Decision Resources

For more information, contact:

Decision Resources, Inc.

Christopher Comfort

781-296-2597

ccomfort@dresources.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook